Duality Biotherapeutics (HKSE:09606) Operating Margin %: -420.18% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09606 Duality Biotherapeutics Inc HKSE:09606
9 GF Score
Price HK$177.80
! 2 Warning Signs
View Full Analysis

What is Duality Biotherapeutics Operating Margin %?

Duality Biotherapeutics HKSE:09606 -1.44% 9 Operating Margin % is -420.18% as of Jun. 2026. GuruFocus rates HKSE:09606 with a GF Score™ of 9/100. The stock has 2 warning signs investors should review. Among 947 Biotechnology companies, Duality Biotherapeutics ranks worse than 57.87% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Duality Biotherapeutics's Operating Income for the six months ended in Jun. 2026 was HK$-1,050.6 Mil. Duality Biotherapeutics's Revenue for the six months ended in Jun. 2026 was HK$250.0 Mil. Therefore, Duality Biotherapeutics's Operating Margin % for the quarter that ended in Jun. 2026 was -420.18%.

The historical rank and industry rank for Duality Biotherapeutics's Operating Margin % or its related term are showing as below:

HKSE:09606' s Operating Margin % Range Over the Past 10 Years
Min: -23103.97   Med: -17.53   Max: 41.45
Current: -179.73


HKSE:09606's Operating Margin % is ranked worse than
57.87% of 947 companies
in the Biotechnology industry
Industry Median: -81.34 vs HKSE:09606: -179.73

Duality Biotherapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Duality Biotherapeutics's Operating Income for the six months ended in Jun. 2026 was HK$-1,050.6 Mil.

Warning Sign:

Duality Biotherapeutics Inc had lost money in 67% of the time over the past 3quarters.


Duality Biotherapeutics  (HKSE:09606) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Duality Biotherapeutics Operating Margin % Related Terms


Duality Biotherapeutics Operating Margin % Historical Data

* Premium members only.

The historical data trend for Duality Biotherapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duality Biotherapeutics Operating Margin % Chart

Duality Biotherapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Operating Margin %
-23,138.19 41.27 -10.86 -25.02

Duality Biotherapeutics Semi-Annual Data
Jun25 Dec25 Jun26
Operating Margin % 9.31 -92.77 -420.18

HKSE:09606 vs VRTX, REGN, MRNA: Operating Margin % Comparison

For the Biotechnology subindustry, Duality Biotherapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Duality Biotherapeutics Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Duality Biotherapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Duality Biotherapeutics's Operating Margin % falls into.


HKSE:09606
9GF Score
Duality Biotherapeutics Inc HKSE:09606
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Duality Biotherapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Duality Biotherapeutics's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-502.44124075849 / 2008.2498838851
=-25.02 %

Duality Biotherapeutics's Operating Margin % for the quarter that ended in Jun. 2026 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2026 ) / Revenue (Q: Jun. 2026 )
=-1050.5768215591 / 250.03175462937
=-420.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -420.18% mean?
Duality Biotherapeutics (HKSE:09606) has a Operating Margin % of -420.18% as of Jun. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Duality Biotherapeutics and its competitors. According to the industry distribution chart, Duality Biotherapeutics ranks #548 out of 947 companies in the Biotechnology industry, placing it in the top 57.9%.
Is Duality Biotherapeutics' Operating Margin % too high?
Duality Biotherapeutics' current Operating Margin % is -420.18%. Based on the distribution chart, Duality Biotherapeutics ranks #548 out of 947 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Duality Biotherapeutics has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Duality Biotherapeutics' Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Duality Biotherapeutics ranks #548 out of 947 companies for Operating Margin %. This places Duality Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Duality Biotherapeutics and its competitors. Duality Biotherapeutics's current Operating Margin % is -420.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duality Biotherapeutics stock overvalued right now?
Duality Biotherapeutics (HKSE:09606) has a current Operating Margin % of -420.18%. The current Operating Margin % is -420.18%. Duality Biotherapeutics' overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Duality Biotherapeutics (HKSE:09606), the current Operating Margin % is -420.18% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Duality Biotherapeutics Business Description

Other Exchanges 4ZB:Germany
Address No. 868 Yinghua Road, 11th Floor, Building A, Jian Gong Datang International Plaza, Pudong New Area, Shanghai, CHN
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
9GF Score

Get the complete analysis for HKSE:09606

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$177.80
Price